Articles tagged with 'Export-TopNews' | Bayer

Newsroom Bayer (Export-TopNews)

2022
September
08,
2022
| 14:59 PM Europe/Amsterdam
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...
Read more
September
01,
2022
| 16:00 PM Europe/Amsterdam
Succeeds Fei-Fei Li, who stepped down at the end of August...
Read more
August
28,
2022
| 09:14 AM Europe/Amsterdam
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...
Read more
August
18,
2022
| 11:00 AM Europe/Amsterdam
Leverkusen, August 18, 2022 – Bayer supports the humanitarian non-profit organization “Fondation suisse de déminage” (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A ...
Read more
August
11,
2022
| 14:00 PM Europe/Amsterdam
Following strong second quarter results, Bayer’s Fields of Opportunity Technology Showcase highlights cutting-edge technologies and pipeline solutions expected to propel farmer productivity, sustainability, and company growth / Featured breakthrough ...
Read more
August
08,
2022
| 08:30 AM Europe/Amsterdam
Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) / Today’s approval under the FDA’s Re...
Read more
August
04,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 9.6 percent (Fx & portfolio adj.) to 12.819 billion euros / EBITDA before special items rises by 30.0 percent to 3.349 billion euros / Crop Science and Consumer Health achieve strong sales and earnings growth / Pharmaceuticals...
Read more
July
14,
2022
| 08:00 AM Europe/Amsterdam
Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022...
Read more
June
29,
2022
| 14:00 PM Europe/Amsterdam
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...
Read more
June
28,
2022
| 14:00 PM Europe/Amsterdam
AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity / Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow / Market introduction t...
Read more
June
23,
2022
| 22:30 PM Europe/Amsterdam
SAN DIEGO - June 23, 2022 - Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorde...
Read more
June
21,
2022
| 12:00 PM Europe/Amsterdam
Berlin, June 21, 2022 - The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with ...
Read more
June
09,
2022
| 14:00 PM Europe/Amsterdam
Innovative business model preserves Vividion’s entrepreneurial culture and pipeline focus, while adding the technical expertise and resources of a global pharma leader / Multiple programs for previously undruggable targets now advancing towards the c...
Read more
June
08,
2022
| 08:00 AM Europe/Amsterdam
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities / Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical tri...
Read more
June
03,
2022
| 09:00 AM Europe/Amsterdam
New post-hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, evaluated the effect of Kerendia™ (finerenone) by baseline HbA1c categories, HbA1c variability, and diabetes duration in patients with chronic kidney d...
Read more
May
31,
2022
| 13:00 PM Europe/Amsterdam
Initiation of global non-interventional study for patients with Parkinson’s planned for the second half of 2022 as next step...
Read more
May
24,
2022
| 09:00 AM Europe/Amsterdam
Pledge commitment to achieve Zero Hunger by 2030 for regions within Asia, Africa and Latin America / Pledge includes large commitment of vegetable and rice seeds which form part of the company's broader sustainability commitments / Bayer will work to...
Read more
May
23,
2022
| 16:39 PM Europe/Amsterdam
Data from the exploratory post hoc analysis of FIDELITY also highlight the potential of Kerendia™ (finerenone) to reduce the incidence of hospitalization for heart failure (HHF), with a more pronounced effect in patients with left ventricular hypertr...
Read more
May
23,
2022
| 14:00 PM Europe/Amsterdam
Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) / The XATOA reg...
Read more
May
19,
2022
| 14:00 PM Europe/Amsterdam
Prostate cancer remains a key focus area with darolutamide data in non-metastatic castration-resistant prostate cancer (high-risk nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride research in metastatic castr...
Read more
May
19,
2022
| 10:00 AM Europe/Amsterdam
Studied in adults with symptomatic chronic heart failure and reduced ejection fraction who are stabilized after a recent decompensation event with IV therapy / Approved in China to reduce the risk of heart failure (HF) hospitalization or the need for...
Read more
May
17,
2022
| 09:00 AM Europe/Amsterdam
New subgroup analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will reveal further insights into the efficacy and safety of Kerendia™ (finerenone) in patients with stage 4 chronic kidney disease (CKD) and type 2 di...
Read more
May
13,
2022
| 14:30 PM Europe/Amsterdam
Investment of approximately 275 million euros in the world’s first learning pharmaceutical production facility / 70 percent lower CO2 emissions than conventional plants...
Read more
May
10,
2022
| 07:30 AM Europe/Amsterdam
Group sales grow by 14.3 percent (Fx & portfolio adj.) to 14.639 billion euros / EBITDA before special items increases by 27.5 percent to 5.251 billion euros / Substantial sales and earnings growth at Crop Science and Consumer Health / Sales up sligh...
Read more
May
03,
2022
| 14:00 PM Europe/Amsterdam
Application is being reviewed concurrently among participating international health authorities under the FDA Oncology Center of Excellence’s (OCE) Project Orbis initiative...
Read more
April
29,
2022
| 10:00 AM Europe/Amsterdam
Operationally and strategically successful in 2021 / Dividend of 2.00 euros per share proposed / Very successful start to 2022...
Read more
April
22,
2022
| 14:00 PM Europe/Amsterdam
Projected transaction supports efforts to accelerate expansion of a diversified portfolio of high-quality microbial-based solutions for growers around the world by further enhancing Bayer’s biologics strategy of tapping into the open innovation ecosy...
Read more
April
22,
2022
| 10:30 AM Europe/Amsterdam
Submission to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for an additional indication in patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Submission based on data from the pivota...
Read more
April
21,
2022
| 15:00 PM Europe/Amsterdam
Berlin, April 21, 2022 - Bayer today announced Tara Frenkl, MD, MPH as the new Head of Oncology Development at its Oncology Strategic Business Unit, effective April 25, 2022. She will report to Christine Roth, Head of the Oncology Strategic Business ...
Read more
April
13,
2022
| 08:40 AM Europe/Amsterdam
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors in adult and pediatric patients in China / In clinical studies of patients with TRK fusion solid tumors, laro...
Read more